All peptides were purchased from Cellmano Biotech Co., Ltd., Hefei, China and InnoPep, San Diego, CA. 4,4'-Bis-bromomethyl-biphenyl (Bph) and 3,3'-Bis-bromomethyl-biphenyl (mBph) were purchased from TCI America and used directly in cross-linking reaction. 4,4'-Bisbromomethyl-bipyridyl (Bpy), p-Phenylene-3,3'bis-allylbromide (Alk), Bis-bromomethylphenazine (Phe), were synthesized according to published procedure (Muppidi, A., et al. Tetrahedron 2014, 70, 7740). Cross-linked peptides were purified using a Gilson or Shimadzu semi-preparative reverse-phase HPLC system equipped with a Phenomenex C18 column with a flow rate of 5 mL/min and a gradient of 10-90% ACN/H2O while monitoring at 220 nm and 254 nm. Analytical HPLC was performed using Phenomenex Luna C18 or Kinetex C18 column (250 × 4.6 mm) with the flow rate set at 1.0 mL/min and UV detection set at 220 and 254 nm. Electrospray LC-MS analysis was performed using a Finnigan LCQ Advantage IonTrap mass spectrometry coupled with a Surveyor HPLC system or using an Agilent 6520 accurate-mass quadrupole-time-of-light (Q-TOF) instrument equipped with reverse phase liquid chromatography and an electrospray ionization (ESI) source.
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Cross-linking reactions: Cross-linking reactions were carried out by incubating the purified cysteine-containing peptides with 1.5 equivalent of cross-linkers (Bph/Bpy/Alk/Phe/mBph) in a mixed acetonitrile/water (1:4 to 2:3 depending on solubility) containing 30 mM NH4HCO3 buffer, pH 8.5, to obtain a final peptide concentration of 1 mM. The mixture was stirred at room temperature for 1.5-2 h. Afterwards the reaction mixture was lyophilized, and the lyophillized powder was washed with diethyl ether to remove excess cross-linker. The residue was dissolved in ACN/H2O, 0.05% TFA and purified by preparative HPLC.
Generation of CRE responsive luciferase stable cell lines:
A CRE responsive luciferase stable HEK 293 cell line overexpressing either human glucagon receptor (GCGR) or glucagon-like peptide-1 receptor (GLP-1R) was generated as follows: HEK293 cells were infected with lentivirus encoding firefly luciferase gene under control of the CRE promoter (Qiagen, Netherlands) and then were selected using 1 µg/mL puromycin (Life technologies, Carlsbad, CA) for 1 week. The surviving cells (referred to as CRE-HEK293) were expanded and then transfected with a G418 selective mammalian expression plasmid encoding human GCGR or GLP-1R, followed by geneticin selection (Life technologies, Carlsbad, CA). Single-colony stable cell lines expressing both CRE-luciferase and GCGR/GLP-1R were then established for in vitro activity assays.
In vitro receptor activation reporter assays: HEK293-GCGR-CRE and HEK293-GLP-1R-CRE cells were seeded in a white 384-well plate at a density of 5,000 cells per well and cultured for 24 hours in DMEM with 10% FBS at 37°C with 5% CO2. Cells were treated with different peptides in a dose dependent manner. After 24 hours, 10 L of Bright-Glo reagent (Promega, Madison, WI) was added to each well and luminescence was determined using an Envision multilabel plate reader (PerkinElmer, Waltham, MA) . The EC50 of each peptide was calculated using GraphPad Prism 6 software (GraphPad, San Diego, CA). Oral glucose tolerance tests (OGTT): CD1 mice were fasted overnight and then administered a subcutaneous dose of 10 µg/mouse of peptide or vehicle control respectively. After 4 hours, mice were orally administered with 3 g of glucose solution per kg body weight and their blood glucose levels were measured before glucose administration (0 min) and after glucose challenge periodically for 2.5hrs. GLP-1R and GCGR reporters were treated with peptides 7, 9 and 11 at varying concentrations for 16 h, and the luminescent signals were acquired using the Bright-Glo TM Luciferase Assay System.
Assays were performed in triplicate and the dose-response curves were fitted to log-agonist vs.
response -variable slope in Prism to generate the EC50 values. Assay was performed in triplicate.
